Filing Details

Accession Number:
0000950170-24-131176
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-26 18:16:40
Reporting Period:
2024-11-22
Accepted Time:
2024-11-26 18:16:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1088856 Corcept Therapeutics Inc CORT Pharmaceutical Preparations (2834) 770487658
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1529655 Charles Gary Robb C/O Corcept Therapeutics Incorporated
101 Redwood Shores Parkway
Redwood City CA 94065
Chief Business Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-11-22 2,609 $56.20 20,163 No 4 S Direct
Common Stock Disposition 2024-11-22 300 $0.00 19,863 No 4 G Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 G Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,665 Indirect Custodial Account for Child
Common Stock 9,665 Indirect Custodial Account for Child
Footnotes
  1. Includes 638 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023, 697 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024, 1,818 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 3, 2024 and 503 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
  2. These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.